STAT
AUGUST 10, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
EMCrit Project
AUGUST 10, 2024
Penetrating Neck Trauma and how to leave the zone EMCrit Project by Scott Weingart, MD FCCM.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
AUGUST 10, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
The Honest Apothecary
AUGUST 10, 2024
“Yep, son, we have met the enemy, and he is us.” – Walt Kelly The line above comes from “Pogo”, the humble and contemplative opossum from Walt Kelly’s long-running mid-20th century comic strip. Here, Pogo is expressing his acknowledgement and disappointment that from an environmental perspective, we are actually the enemy.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTech
AUGUST 10, 2024
With the agreement, Andelyin Biosciences will add MyoAAV plasmids developed by Broad Institute of MIT and Harvard to its AAV Curator Platform.
Pharmacy Times
AUGUST 10, 2024
Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.
Pharmacy Times
AUGUST 10, 2024
The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.
Expert insights. Personalized for you.
238 
Let's personalize your content